Myopericytoma arising from myopericytosis-a hitherto unrecognized entity within the lung. 2021

Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
Institute of Pathology, Helios Clinics, Gauting, Germany.

Two cases of myopericytosis combined with pericytoma originating within the lung are reported. These are rare pulmonary tumors. The differential diagnosis for hemangiopericytoma and pericytic tumors with glomus elements is discussed. Both myopericytic lesions mimic other lesions, which are more commonly seen in the lung. Based on the expression of vascular growth factor receptors 2 and 3, an antiangiogenic therapy was suggested for the patient with the myopericytoma. A treatment with an angiogenesis inhibitor resulted in a regression of the tumor, but not the precursor lesion. Probably a more specific therapy using tyrosine kinase inhibitors for VEGFR2/3 might better control these myopericytic proliferations.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077777 Myopericytoma Rare myofibroma-like perivascular soft tissue tumor, usually benign, characterized by concentric perivascular proliferation. Myopericytomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
January 1988, The American journal of gastroenterology,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
November 1994, The Journal of pathology,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
September 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
November 1933, Annals of surgery,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
April 1962, Science (New York, N.Y.),
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
March 1966, The Journal of urology,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
February 1953, McGill medical journal,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
November 2007, Journal of cutaneous pathology,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
November 1986, Schweizerische medizinische Wochenschrift,
Ulrike Gruber-Moesenbacher, and Alicia Morresi-Hauff, and Katja Behr, and Helmut Popper
July 2018, The American journal of surgical pathology,
Copied contents to your clipboard!